Lmr Partners LLP Cyma Bay Therapeutics, Inc. Transaction History

Lmr Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $151,392 - $246,913	25,747 Added 63.57%	66,251 $577,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $32,663 - $63,602	10,144 Added 33.41%	40,504 $253,000
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $52,219 - $102,920	30,360 New	30,360 $90,000
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $1.11 Million - $1.8 Million	-890,894 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $1.18 Million - $5.28 Million	890,894 New	890,894 $1.75 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.